The representative COVID-19 cohort Munich (KoCo19): from the beginning of the pandemic to the Delta virus variant
Le Gleut R, Plank M, Pütz P, Radon K, Bakuli A, Rubio-Acero R, Paunovic I, Rieß F, Winter S, Reinkemeyer C, Schälte Y, et al. (2023)
BMC Infectious Diseases 23(1): 466.
Zeitschriftenaufsatz
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Le Gleut, Ronan;
Plank, Michael;
Pütz, PeterUniBi;
Radon, Katja;
Bakuli, Abhishek;
Rubio-Acero, Raquel;
Paunovic, Ivana;
Rieß, Friedrich;
Winter, Simon;
Reinkemeyer, Christina;
Schälte, Yannik;
Olbrich, Laura
Alle
Alle
Einrichtung
Abstract / Bemerkung
**Background**
Population-based serological studies allow to estimate prevalence of SARS-CoV-2 infections despite a substantial number of mild or asymptomatic disease courses. This became even more relevant for decision making after vaccination started. The KoCo19 cohort tracks the pandemic progress in the Munich general population for over two years, setting it apart in Europe. **Methods**
Recruitment occurred during the initial pandemic wave, including 5313 participants above 13 years from private households in Munich. Four follow-ups were held at crucial times of the pandemic, with response rates of at least 70%. Participants filled questionnaires on socio-demographics and potential risk factors of infection. From Follow-up 2, information on SARS-CoV-2 vaccination was added. SARS-CoV-2 antibody status was measured using the Roche Elecsys® Anti-SARS-CoV-2 anti-N assay (indicating previous infection) and the Roche Elecsys® Anti-SARS-CoV-2 anti-S assay (indicating previous infection and/or vaccination). This allowed us to distinguish between sources of acquired antibodies. **Results**
The SARS-CoV-2 estimated cumulative sero-prevalence increased from 1.6% (1.1-2.1%) in May 2020 to 14.5% (12.7-16.2%) in November 2021. Underreporting with respect to official numbers fluctuated with testing policies and capacities, becoming a factor of more than two during the second half of 2021. Simultaneously, the vaccination campaign against the SARS-CoV-2 virus increased the percentage of the Munich population having antibodies, with 86.8% (85.5-87.9%) having developed anti-S and/or anti-N in November 2021. Incidence rates for infections after (BTI) and without previous vaccination (INS) differed (ratio INS/BTI of 2.1, 0.7-3.6). However, the prevalence of infections was higher in the non-vaccinated population than in the vaccinated one. Considering the whole follow-up time, being born outside Germany, working in a high-risk job and living area per inhabitant were identified as risk factors for infection, while other socio-demographic and health-related variables were not. Although we obtained significant within-household clustering of SARS-CoV-2 cases, no further geospatial clustering was found. **Conclusions**
Vaccination increased the coverage of the Munich population presenting SARS-CoV-2 antibodies, but breakthrough infections contribute to community spread. As underreporting stays relevant over time, infections can go undetected, so non-pharmaceutical measures are crucial, particularly for highly contagious strains like Omicron.
Population-based serological studies allow to estimate prevalence of SARS-CoV-2 infections despite a substantial number of mild or asymptomatic disease courses. This became even more relevant for decision making after vaccination started. The KoCo19 cohort tracks the pandemic progress in the Munich general population for over two years, setting it apart in Europe. **Methods**
Recruitment occurred during the initial pandemic wave, including 5313 participants above 13 years from private households in Munich. Four follow-ups were held at crucial times of the pandemic, with response rates of at least 70%. Participants filled questionnaires on socio-demographics and potential risk factors of infection. From Follow-up 2, information on SARS-CoV-2 vaccination was added. SARS-CoV-2 antibody status was measured using the Roche Elecsys® Anti-SARS-CoV-2 anti-N assay (indicating previous infection) and the Roche Elecsys® Anti-SARS-CoV-2 anti-S assay (indicating previous infection and/or vaccination). This allowed us to distinguish between sources of acquired antibodies. **Results**
The SARS-CoV-2 estimated cumulative sero-prevalence increased from 1.6% (1.1-2.1%) in May 2020 to 14.5% (12.7-16.2%) in November 2021. Underreporting with respect to official numbers fluctuated with testing policies and capacities, becoming a factor of more than two during the second half of 2021. Simultaneously, the vaccination campaign against the SARS-CoV-2 virus increased the percentage of the Munich population having antibodies, with 86.8% (85.5-87.9%) having developed anti-S and/or anti-N in November 2021. Incidence rates for infections after (BTI) and without previous vaccination (INS) differed (ratio INS/BTI of 2.1, 0.7-3.6). However, the prevalence of infections was higher in the non-vaccinated population than in the vaccinated one. Considering the whole follow-up time, being born outside Germany, working in a high-risk job and living area per inhabitant were identified as risk factors for infection, while other socio-demographic and health-related variables were not. Although we obtained significant within-household clustering of SARS-CoV-2 cases, no further geospatial clustering was found. **Conclusions**
Vaccination increased the coverage of the Munich population presenting SARS-CoV-2 antibodies, but breakthrough infections contribute to community spread. As underreporting stays relevant over time, infections can go undetected, so non-pharmaceutical measures are crucial, particularly for highly contagious strains like Omicron.
Erscheinungsjahr
2023
Zeitschriftentitel
BMC Infectious Diseases
Band
23
Ausgabe
1
Art.-Nr.
466
Urheberrecht / Lizenzen
eISSN
1471-2334
Page URI
https://pub.uni-bielefeld.de/record/2980935
Zitieren
Le Gleut R, Plank M, Pütz P, et al. The representative COVID-19 cohort Munich (KoCo19): from the beginning of the pandemic to the Delta virus variant. BMC Infectious Diseases. 2023;23(1): 466.
Le Gleut, R., Plank, M., Pütz, P., Radon, K., Bakuli, A., Rubio-Acero, R., Paunovic, I., et al. (2023). The representative COVID-19 cohort Munich (KoCo19): from the beginning of the pandemic to the Delta virus variant. BMC Infectious Diseases, 23(1), 466. https://doi.org/10.1186/s12879-023-08435-1
Le Gleut, Ronan, Plank, Michael, Pütz, Peter, Radon, Katja, Bakuli, Abhishek, Rubio-Acero, Raquel, Paunovic, Ivana, et al. 2023. “The representative COVID-19 cohort Munich (KoCo19): from the beginning of the pandemic to the Delta virus variant”. BMC Infectious Diseases 23 (1): 466.
Le Gleut, R., Plank, M., Pütz, P., Radon, K., Bakuli, A., Rubio-Acero, R., Paunovic, I., Rieß, F., Winter, S., Reinkemeyer, C., et al. (2023). The representative COVID-19 cohort Munich (KoCo19): from the beginning of the pandemic to the Delta virus variant. BMC Infectious Diseases 23:466.
Le Gleut, R., et al., 2023. The representative COVID-19 cohort Munich (KoCo19): from the beginning of the pandemic to the Delta virus variant. BMC Infectious Diseases, 23(1): 466.
R. Le Gleut, et al., “The representative COVID-19 cohort Munich (KoCo19): from the beginning of the pandemic to the Delta virus variant”, BMC Infectious Diseases, vol. 23, 2023, : 466.
Le Gleut, R., Plank, M., Pütz, P., Radon, K., Bakuli, A., Rubio-Acero, R., Paunovic, I., Rieß, F., Winter, S., Reinkemeyer, C., Schälte, Y., Olbrich, L., Hannes, M., Kroidl, I., Noreña, I., Janke, C., Wieser, A., Hoelscher, M., Fuchs, C., Castelletti, N., Ahmed, M.I.M., Alamoudi, E., Anderson, J., Baldassarre, V., Baumann, M., Becker, M., Bednarski, F., Behlen, M., Bemirayev, O., Beyerl, J., Bitzer, P., Böhnlein, R., Brand, I., Brauer, A., Britz, V., Bruger, J., Bünz, F., Caroli, F., Coleman, J., Contento, L., Czwienzek, A., Deák, F., Diefenbach, M.N., Diepers, P., Do, A., Dobler, G., Durner, J., Eser, T., Eberle, U., Eckstein, J., Falk, P., Feyereisen, M., Fingerle, V., Fischer, S., Frese, J., Forster, F., Fröschl, G., Geisenberger, O., Garí, M., Gasser, M., Gauder, S., Geier, R., Gillig, K., Geldmacher, C., Gezgin, K., Gilberg, L., Gillig, K., Girl, P., Golschan, E., Grauvogl, V., Noller, J.M.G., Guglielmini, E.M., Gutierrez, P., Haderer, A., Halfmann, C., Hartinger, L., Haselwarter, T., Hasenauer, J., Hernandez, A., Heller, L., Heiber, A., Herrmann, M., Hillari, L., Hillmann, S., Hinske, C., Hoefflin, J., Hofberger, T., Höfinger, M., Hofmann, L., Horn, S., Huber, K., Janke, C., Karger, L., Kappl, U., Keßler, A., Khan, Z., Kiani, C., Klugherz, I., Kreider, N., Kresin, J., Kroidl, A., Kunder, P., Lang, M., Lang, C., Lange, S., Lapteva, E., Laxy, M., Leidl, R., Liedl, L., Lindner, F., Lucaj, X., Lucke, E., Luppa, F., Nafziger, A.S., Maczka, A., Mang, P., Markgraf, A., Matcau, P., Mayrhofer, R., Mekota, A.-M., Metaxa, D., Mohr, E., Müller, H., Müller, K., Nascimento, N., Niermeyer, K., Nikolaides, S., Pattard, L., Pleimelding, C., Pletschette, M., Poll, V., Prückner, S., Puchinger, K., Pusl, K., Raimúndez, E., Raschka, J., Reich, J., Reinkemeyer, C., Rothe, C., Ruci, V., Saathoff, E., Schäfer, N., Schandelmaier, P., Schluse, B., Schneider, A., Schneider, L., Schultz, S., Schunk, M., Schwettmann, L., Sedlmeier, J., Sintu-Sempta, L., Soler, A., Sothmann, P., Strobl, K., Strüber, A., Strüber, L., Tang, J., Theis, F., Thiel, V., Thumser, E., Thur, N., Ullrich, J., Vollmayr, V., Von Lovenberg, E., Von Lovenberg, J., Vos, C., Waibel, J., Wallrauch, C., Weigl, N., Wölfl, R., Wolff, J., Wullinger, P., Würfel, T., Wustrow, P., Zange, S., Zeggini, E., Zielke, A., Zimmer, T., Zimmermann, T., Zielke, A., Zuche, L.: The representative COVID-19 cohort Munich (KoCo19): from the beginning of the pandemic to the Delta virus variant. BMC Infectious Diseases. 23, : 466 (2023).
Le Gleut, Ronan, Plank, Michael, Pütz, Peter, Radon, Katja, Bakuli, Abhishek, Rubio-Acero, Raquel, Paunovic, Ivana, Rieß, Friedrich, Winter, Simon, Reinkemeyer, Christina, Schälte, Yannik, Olbrich, Laura, Hannes, Marlene, Kroidl, Inge, Noreña, Ivan, Janke, Christian, Wieser, Andreas, Hoelscher, Michael, Fuchs, Christiane, Castelletti, Noemi, Ahmed, Mohamed Ibraheem Mohamed, Alamoudi, Emad, Anderson, Jared, Baldassarre, Valeria, Baumann, Maximilian, Becker, Marc, Bednarski, Franziska, Behlen, Marieke, Bemirayev, Olimbek, Beyerl, Jessica, Bitzer, Patrick, Böhnlein, Rebecca, Brand, Isabel, Brauer, Anna, Britz, Vera, Bruger, Jan, Bünz, Franziska, Caroli, Friedrich, Coleman, Josephine, Contento, Lorenzo, Czwienzek, Alina, Deák, Flora, Diefenbach, Maximilian N., Diepers, Paulina, Do, Anna, Dobler, Gerhard, Durner, Jürgen, Eser, Tabea, Eberle, Ute, Eckstein, Judith, Falk, Philine, Feyereisen, Manuela, Fingerle, Volker, Fischer, Stefanie, Frese, Jonathan, Forster, Felix, Fröschl, Günter, Geisenberger, Otto, Garí, Mercè, Gasser, Marius, Gauder, Sonja, Geier, Raffaela, Gillig, Kristina, Geldmacher, Christof, Gezgin, Keisha, Gilberg, Leonard, Gillig, Kristina, Girl, Philipp, Golschan, Elias, Grauvogl, Vitus, Noller, Jessica Michelle Guggenbuehl, Guglielmini, Elena Maria, Gutierrez, Pablo, Haderer, Anselm, Halfmann, Celina, Hartinger, Lena, Haselwarter, Timm, Hasenauer, Jan, Hernandez, Alejandra, Heller, Luca, Heiber, Arlett, Herrmann, Matthias, Hillari, Leah, Hillmann, Stefan, Hinske, Christian, Hoefflin, Janna, Hofberger, Tim, Höfinger, Michael, Hofmann, Larissa, Horn, Sacha, Huber, Kristina, Janke, Christian, Karger, Lilian, Kappl, Ursula, Keßler, Antonia, Khan, Zohaib, Kiani, Charlotte, Klugherz, Isabel, Kreider, Norah, Kresin, Johanna, Kroidl, Arne, Kunder, Pratik, Lang, Magdalena, Lang, Clemens, Lange, Silvan, Lapteva, Ekaterina, Laxy, Michael, Leidl, Reiner, Liedl, Leopold, Lindner, Felix, Lucaj, Xhovana, Lucke, Elisabeth, Luppa, Fabian, Nafziger, Alexandra Sophie, Maczka, Alexander, Mang, Petra, Markgraf, Alisa, Matcau, Paula, Mayrhofer, Rebecca, Mekota, Anna-Maria, Metaxa, Dafni, Mohr, Emily, Müller, Hannah, Müller, Katharina, Nascimento, Nathalia, Niermeyer, Kasimir, Nikolaides, Sophia, Pattard, Leonie, Pleimelding, Claire, Pletschette, Michel, Poll, Viona, Prückner, Stephan, Puchinger, Kerstin, Pusl, Konstantin, Raimúndez, Elba, Raschka, Julius, Reich, Jakob, Reinkemeyer, Christina, Rothe, Camilla, Ruci, Viktoria, Saathoff, Elmar, Schäfer, Nicole, Schandelmaier, Paul, Schluse, Benedikt, Schneider, Annika, Schneider, Lara, Schultz, Sophie, Schunk, Mirjam, Schwettmann, Lars, Sedlmeier, Josefin, Sintu-Sempta, Linda, Soler, Alba, Sothmann, Peter, Strobl, Katharina, Strüber, Aida, Strüber, Laura, Tang, Jeni, Theis, Fabian, Thiel, Verena, Thumser, Eva, Thur, Niklas, Ullrich, Julian, Vollmayr, Vincent, Von Lovenberg, Emilia, Von Lovenberg, Jonathan, Vos, Carsten, Waibel, Julia, Wallrauch, Claudia, Weigl, Nikolas, Wölfl, Roman, Wolff, Julia, Wullinger, Pia, Würfel, Tobias, Wustrow, Patrick, Zange, Sabine, Zeggini, Eleftheria, Zielke, Anna, Zimmer, Thorbjörn, Zimmermann, Thomas, Zielke, Anna, and Zuche, Lea. “The representative COVID-19 cohort Munich (KoCo19): from the beginning of the pandemic to the Delta virus variant”. BMC Infectious Diseases 23.1 (2023): 466.
Daten bereitgestellt von European Bioinformatics Institute (EBI)
Zitationen in Europe PMC
Daten bereitgestellt von Europe PubMed Central.
References
Daten bereitgestellt von Europe PubMed Central.
Export
Markieren/ Markierung löschen
Markierte Publikationen
Web of Science
Dieser Datensatz im Web of Science®Quellen
PMID: 37442952
PubMed | Europe PMC
Suchen in
Google Scholar